Literature DB >> 19697956

Metal ion interactions in the DNA cleavage/ligation active site of human topoisomerase IIalpha.

Joseph E Deweese1, F Peter Guengerich, Alex B Burgin, Neil Osheroff.   

Abstract

Human topoisomerase IIalpha utilizes a two-metal-ion mechanism for DNA cleavage. One of the metal ions (M(1)(2+)) is believed to make a critical interaction with the 3'-bridging atom of the scissile phosphate, while the other (M(2)(2+)) is believed to interact with a nonbridging oxygen of the scissile phosphate. Based on structural and mutagenesis studies of prokaryotic nucleic acid enzymes, it has been proposed that the active site divalent metal ions interact with type II topoisomerases through a series of conserved acidic amino acid residues. The homologous residues in human topoisomerase IIalpha are E461, D541, D543, and D545. To address the validity of these assignments and to delineate interactions between individual amino acids and M(1)(2+) and M(2)(2+), we individually mutated each of these acidic amino acid residues in topoisomerase IIalpha to either cysteine or alanine. Mutant enzymes displayed a marked loss of catalytic and DNA cleavage activity as well as a reduced affinity for divalent metal ions. Additional experiments determined the ability of wild-type and mutant topoisomerase IIalpha enzymes to cleave an oligonucleotide substrate that contained a sulfur atom in place of the 3'-bridging oxygen of the scissile phosphate in the presence of Mg2+, Mn2+, or Ca2+. On the basis of the results of these studies, we conclude that the four acidic amino acid residues interact with metal ions in the DNA cleavage/ligation active site of topoisomerase IIalpha. Furthermore, we propose that M(1)(2+) interacts with E461, D543, and D545 and M(2)(2+) interacts with E461 and D541.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19697956      PMCID: PMC2782489          DOI: 10.1021/bi900875c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  39 in total

Review 1.  DNA topoisomerases: structure, function, and mechanism.

Authors:  J J Champoux
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

Review 2.  Intracellular magnesium and magnesium buffering.

Authors:  Robert D Grubbs
Journal:  Biometals       Date:  2002-09       Impact factor: 2.949

3.  Structural similarities between topoisomerases that cleave one or both DNA strands.

Authors:  J M Berger; D Fass; J C Wang; S C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

Review 4.  Eukaryotic DNA topoisomerase II beta.

Authors:  C A Austin; K L Marsh
Journal:  Bioessays       Date:  1998-03       Impact factor: 4.345

Review 5.  Appendix. II: Alignment of primary sequences of DNA topoisomerases.

Authors:  P R Caron; J C Wang
Journal:  Adv Pharmacol       Date:  1994

6.  Thiophilic metal ion rescue of phosphorothioate interference within the Tetrahymena ribozyme P4-P6 domain.

Authors:  S Basu; S A Strobel
Journal:  RNA       Date:  1999-11       Impact factor: 4.942

7.  Spontaneous DNA lesions poison human topoisomerase IIalpha and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints.

Authors:  P S Kingma; C A Greider; N Osheroff
Journal:  Biochemistry       Date:  1997-05-20       Impact factor: 3.162

8.  Use of divalent metal ions in the dna cleavage reaction of human type II topoisomerases.

Authors:  Joseph E Deweese; Amber M Burch; Alex B Burgin; Neil Osheroff
Journal:  Biochemistry       Date:  2009-03-10       Impact factor: 3.162

9.  A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.

Authors:  S H Elsea; Y Hsiung; J L Nitiss; N Osheroff
Journal:  J Biol Chem       Date:  1995-01-27       Impact factor: 5.157

10.  Coordinating the two protomer active sites of human topoisomerase IIalpha: nicks as topoisomerase II poisons.

Authors:  Joseph E Deweese; Neil Osheroff
Journal:  Biochemistry       Date:  2009-02-24       Impact factor: 3.162

View more
  7 in total

Review 1.  The use of divalent metal ions by type II topoisomerases.

Authors:  Joseph E Deweese; Neil Osheroff
Journal:  Metallomics       Date:  2010-05-21       Impact factor: 4.526

2.  The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage.

Authors:  Timothy J Wendorff; Bryan H Schmidt; Pauline Heslop; Caroline A Austin; James M Berger
Journal:  J Mol Biol       Date:  2012-07-25       Impact factor: 5.469

Review 3.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

4.  A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases.

Authors:  Bryan H Schmidt; Alex B Burgin; Joseph E Deweese; Neil Osheroff; James M Berger
Journal:  Nature       Date:  2010-06-03       Impact factor: 49.962

5.  Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV.

Authors:  Steven L Pitts; Grace F Liou; Lesley A Mitchenall; Alex B Burgin; Anthony Maxwell; Keir C Neuman; Neil Osheroff
Journal:  Nucleic Acids Res       Date:  2011-02-07       Impact factor: 16.971

6.  A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance.

Authors:  Thomas Germe; Judit Vörös; Frederic Jeannot; Thomas Taillier; Robert A Stavenger; Eric Bacqué; Anthony Maxwell; Benjamin D Bax
Journal:  Nucleic Acids Res       Date:  2018-05-04       Impact factor: 16.971

7.  A Gold Nanoparticle Nanonuclease Relying on a Zn(II) Mononuclear Complex.

Authors:  Joanna Czescik; Susanna Zamolo; Tamis Darbre; Riccardo Rigo; Claudia Sissi; Adam Pecina; Laura Riccardi; Marco De Vivo; Fabrizio Mancin; Paolo Scrimin
Journal:  Angew Chem Int Ed Engl       Date:  2020-11-16       Impact factor: 15.336

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.